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OBJECTIVES The purpose of our study was to determine if the presence of African American ethnicity
modulates improvement in coronary vascular endothelial function after supplementary
L-arginine.
BACKGROUND Endothelial dysfunction is an early stage in the development of coronary atherosclerosis and
has been implicated in the pathogenesis of hypertension and cardiomyopathy. Amelioration
of endothelial dysfunction has been demonstrated in patients with established coronary
atherosclerosis or with risk factors in response to infusion of L-arginine, the precursor of
nitric oxide. Racial and gender patterns in L-arginine responsiveness have not, heretofore,
been studied.
METHODS Invasive testing of coronary artery and microvascular reactivity in response to graded
intracoronary infusions of acetylcholine (ACh)  L-arginine was carried out in 33 matched
pairs of African American and white subjects with no angiographic coronary artery disease.
Pairs were matched for age, gender, indexed left ventricular mass, body mass index and
low-density lipoprotein cholesterol.
RESULTS In addition to the matching parameters, there were no significant differences in peak coronary
blood flow (CBF) response to intracoronary adenosine or in the peak CBF response to ACh
before L-arginine infusion. However, absolute percentile improvement in CBF response to
ACh infusion after L-arginine, as compared with before, was significantly greater among
African Americans as a group (45  10% vs. 4  6%, p  0.0016) and after partitioning by
gender. The mechanism of this increase was mediated through further reduction in coronary
microvascular resistance. L-arginine infusion also resulted in greater epicardial dilator
response after ACh among African Americans.
CONCLUSIONS We conclude that intracoronary infusion of L-arginine provides significantly greater aug-
mentation of endothelium-dependent vascular relaxation in those of African American
ethnicity when compared with matched white subjects drawn from a cohort electively referred
for coronary angiography. Our findings suggest that there are target populations in which
supplementary L-arginine may be of therapeutic benefit in the amelioration of microvascular
endothelial dysfunction. In view of the excess prevalence of cardiomyopathy among African
Americans, pharmacologic correction of microcirculatory endothelial dysfunction in this
group is an important area of further investigation and may ultimately prove to be clinically
indicated. (J Am Coll Cardiol 2002;39:1314–22) © 2002 by the American College of
Cardiology Foundation
Endothelial dysfunction represents an early pre-clinical
stage in the evolution of coronary atherosclerosis and has
been implicated in the pathogenesis of other cardiovascular
diseases, including systemic hypertension and dilated car-
diomyopathy (1–5). One indicator of endothelial dysfunc-
tion is impaired vasodilator response to intracoronary ace-
tylcholine (ACh) (6–13). This occurs when coronary
vasorelaxation after stimulated release of endothelial nitric
oxide (NO) is exceeded by constriction mediated through
direct stimulation of muscarinic receptors on vascular
smooth muscle cells. A proposed approach for treatment of
endothelial dysfunction is provision of supplementary
L-arginine, the precursor of NO. Despite the fact that
sufficient intracellular L-arginine exists in theory to maxi-
mally drive the reaction leading from L-arginine to NO
through constitutive NO synthase, a number of studies have
demonstrated improvement in systemic, forearm and coro-
nary endothelial function after infusion or ingestion of
L-arginine (14–21). Many of these studies included pa-
tients with established coronary atherosclerotic disease
(CAD) or with risk factors for CAD. Furthermore, other
investigations have demonstrated that systemic administra-
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tion of L-arginine results in transient reduction in systemic
vascular resistance and blood pressure in both normotensive
and hypertensive humans and in the salt-sensitive rat model
of hypertension (22–26). Previous studies have not ad-
dressed racial and gender patterns in L-arginine responsive-
ness. Thus, the purpose of our study was to examine the
possible modulating effects of race and gender on response
of the coronary endothelium to intracoronary infusion of
L-arginine.
METHODS
Subjects. Patients were prospectively recruited for the ap-
proved investigational study (Albany Medical College In-
stitutional Review Board) after clinical referral for cardiac
catheterization. Informed consent was obtained document-
ing the participants’ understanding of the investigational
nature of the protocol. The current investigation is part of a
larger study begun in 1992 whose purpose was the exami-
nation of the effects of coronary risk factors, gender and
ethnicity on coronary artery and arteriolar relaxation prop-
erties. Ethnicity was self-reported by the patient as African
American (black) or Caucasian (white). No patient had
CAD based on angiographic assessment. Individuals were
excluded from the study because of significant valvular heart
disease, prior history of myocardial infarction or coronary
revascularization procedure, or other serious medical disor-
der. Patients were excluded for morbid obesity, defined as
weight greater than twice ideal body weight.
African American and Caucasian study pairs were
matched first for gender, then for the best overall fit of the
parameters: age, left ventricular mass indexed by body
surface area (LVMI), body mass index (BMI) and low-
density lipoprotein cholesterol (LDLC). For age, differences
were considered less clinically significant among those 20 to
35 years old. The parameters of age, LVMI, BMI and
LDLC were selected for matching because of their previ-
ously reported adverse effects on endothelial function and
because the latter three were found to differ significantly
among African American and white subjects enrolled in our
larger study. Hypertension was defined as reproducible
blood pressure measurements 140/90 mm Hg or self-
reported taking of antihypertensive medication. Diabetes
mellitus was diagnosed by self-reported history or fasting
serum glucose 126 mg/dl. Hypercholesterolemia was de-
fined by LDLC 160 mg/dl or by current use of
cholesterol-lowering medication. A risk factor score was
calculated for each patient by adding one point for each of
the following risk factors for CAD: male gender and age
45 years, female gender and age 55 years, hypertension,
cigarette smoking, diabetes mellitus, LDLC 160 mg/dl,
high-density lipoprotein cholesterol (HDLC) 40 mg/dl
and BMI30 kg/m2. One point was subtracted for HDLC
60 mg/dl. Menopausal status was determined based on
self-reported history. Blood was obtained in the fasting state
for measurement of total cholesterol, LDLC, HDLC,
lipoprotein(a) and glucose.
Left ventricular (LV) mass was calculated using M-mode
echocardiographic measurements made in accordance with
the PENN convention and corrected to agree with necropsy
data (27,28). Analyses were performed using LV mass
indexed first by body surface area in m2 and second by
height2.7 in m2.7. Gender specific partition values for LV
hypertrophy were taken from the Framingham Heart study
(29). Subjects fasted for a minimum of 8 h before the study.
Current smokers were instructed to refrain from smoking
for a minimum of 8 h. Coronary endothelial dysfunction
was defined by one or more of the following: presence of risk
factors for CAD, constriction of epicardial arteries during
infusion of ACh and coronary blood flow (CBF) increase
150% above baseline during infusion of ACh (1,4,9–12).
Invasive coronary artery testing. After coronary angiog-
raphy was performed, a 0.018-in. Cardiometrics Flo-Wire
Doppler tipped guidewire (Cardiometrics, Mountain View,
California) was advanced through a coronary guiding cath-
eter into the proximal to mid-portion of the left anterior
descending artery in 26 African American and in 25
Caucasian subjects and into the circumflex artery in 7 and 8,
respectively. After stable measurements of baseline coronary
flow velocity were recorded, we infused agents into the left
main artery to test the capacity for vasorelaxation by
endothelium-dependent and -independent mechanisms. In-
stantaneous coronary pressure and blood flow velocity were
continuously recorded. Coronary arteriograms were ob-
tained under baseline conditions, at the end of each graded
infusion of ACh and after L-arginine and repeated peak
infusion of ACh.
Intracoronary drug infusion protocols. To evaluate
endothelium-independent coronary relaxation of the micro-
circulation, adenosine was administered by graded intra-
coronary bolus into the left main artery (8 g, then 16 g,
then 20 g), each after return to baseline values of coronary
flow velocity, blood pressure and heart rate. Graded infusion
of ACh was then commenced to study endothelium-
dependent coronary relaxation of resistance and conduit
vessels. Acetylcholine in 3 ml was infused directly into the
left main artery (assumed blood flow equal to 150 ml/min)
over 2 min initially at a rate of 0.15 g/min (108 mol/l)
Abbreviations and Acronyms
ACh  acetylcholine
ADMA  asymmetric dimethylarginine
ANOVA  analysis of variance
BMI  body mass index
CAD  coronary atherosclerotic disease
CBF  coronary blood flow
HDLC  high-density lipoprotein cholesterol
LDLC  low-density lipoprotein cholesterol
LV  left ventricle/ventricular
LVMI  left ventricular mass indexed by body surface
area
NO  nitric oxide
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using a Medfusion syringe pump (Harvard apparatus, Du-
luth, Georgia). Acetylcholine was similarly infused at 1.5
g/min (107 mol/l), then 15 g/min (10 6 mol/l). In 48
patients (73%), a peak infusion rate of 30 g/min (2 106
mol/l) was additionally administered. After ACh infusions,
L-arginine (3,200 moles) was infused over 10 min into the
left main coronary artery and the peak infusion rate of ACh
repeated.
Quantitative coronary angiography. Baseline arteriogra-
phy of the coronary artery undergoing study was performed
in an optimal right anterior oblique or anteroposterior
projection so that overlapping of branches and foreshorten-
ing of the region of interest were minimized. An optimal
end-diastolic cineangiographic frame was selected, and cor-
onary artery diameter was measured at the site of Doppler
velocity measurements in each of the sequential research
study arteriograms. Measurements were made with elec-
tronic digital calipers (Sandhill Scientific, Colorado Springs,
Colorado) by a single investigator (J. L. H.) who was
blinded to the clinical, echocardiographic and Doppler
velocity findings. We have previously shown by linear
regression analysis that intraobserver variability for measure-
ment of coronary artery diameter in our laboratory was
minimal (30). Coronary artery area was calculated assuming
a circular cross-sectional profile. Percent change in coronary
artery diameter above baseline (a measure of epicardial
artery vasomotor function) was calculated in response to
infusions of ACh  L-arginine. The contrast agent iohexol
was used for all studies.
Coronary artery blood flow and resistance measurements.
Coronary artery blood flow was calculated as the product of
mean CBF velocity and corresponding coronary artery
cross-sectional area. Baseline values were calculated before
infusion of the predominantly endothelium-independent
agent adenosine and before infusion of the endothelium-
dependent agent ACh. Percent change in CBF above
baseline was calculated in response to adenosine, in response
to each infusion of ACh and after co-infusion of the peak
dose of ACh  L-arginine. Similarly, coronary vascular
resistance was calculated as the quotient of instantaneous
coronary perfusion pressure (mean aortic pressure) and
mean CBF. Minimum endothelium-dependent coronary
vascular resistance index was calculated as the coronary
vascular resistance at peak effect of ACh divided by that at
baseline and expressed as a percentage. After L-arginine and
repeated peak infusion of ACh, minimum coronary vascular
resistance index was recalculated.
Statistical analysis. Summary clinical data and outcomes
of the research studies (percentile change in CBF and
coronary artery diameter measurements in response to
ACh  L-arginine as compared with ACh alone) are
expressed as mean  SE. Unpaired Student t test (for
continuous variables) and chi-square test or Fisher exact test
(for categorical variables) were used for assessment of the
statistical significance of group differences, where a value of
p 0.05 was considered significant. Patients were grouped
by race and by race and gender for comparisons. The
primary outcome for this study, change in the peak ACh
microvascular response after intracoronary L-arginine, was
defined as the absolute percentage point increase in CBF
after L-arginine during peak infusion of ACh when com-
pared with control ACh testing before L-arginine. Simi-
larly, change in the peak ACh epicardial response after
intracoronary L-arginine was defined as the absolute per-
centage point increase in epicardial diameter after
L-arginine during peak infusion of ACh when compared
with control ACh testing. Percentile change in the ACh
stimulated minimum coronary vascular resistance index in
response to supplementary L-arginine infusion was calcu-
lated for each subject, then compared among the groups.
Two-way analysis of variance (ANOVA) was used to test
for gender and racial differences in CBF and coronary artery
diameter responses to graded infusions of ACh, with the
Bonferroni adjustment of probability values for multiple
comparisons. Linear regression analysis was performed for
assessment of the association between ACh response after
L-arginine and the independent variables: age, LVMI,
BMI, LDLC, HDLC, lipoprotein(a), adenosine response,
mean arterial pressure and risk factor score. Grubbs test was
used for detection of outliers (31).
RESULTS
Subjects. Thirty-three African American subjects (20 men
and 13 women) were identified as eligible for the study and
were subsequently matched with 33 Caucasian subjects.
Eligibility was defined as performance of coronary reserve
and endothelial function testing with supplementary
L-arginine infusion, presence of endothelial dysfunction as
defined in the Methods section, absence of any study
exclusion and presence of a matching white subject fulfilling
the same criteria. African American and white subjects were
matched first for gender, then for the closest overall match
of age, LVMI, LDLC and BMI. Matching parameters and
pertinent clinical data for African American patients are
listed in Table 1. Similarly, the paired white subjects are
listed sequentially using the same format in Table 2. Also
listed is the percentile change in peak CBF response
stimulated by ACh after L-arginine compared with before.
Table 3 presents summary matching data for the two
groups. There were no significant differences in matching
parameters, in baseline peak ACh CBF responses (76  9%
vs. 86  10% increase above baseline) and in peak
endothelium-independent (adenosine) CBF responses
(208  13% vs. 174  12% increase above baseline) among
African American and white subjects. Using two-way
ANOVA, dose response curves relating percent increase in
CBF to dose of ACh were not significantly different among
the African American and Caucasian groups. Similarly,
there were no significant differences among groups in dose
response curves relating percent increase in coronary diam-
eter to dose of ACh. Hypertension was equally present in
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73% of the two groups. Chronic tobacco use, diabetes
mellitus and hyperlipidemia were present in similar propor-
tions, 30% versus 27%, 18% versus 21% and 24% versus
12%, respectively, p  NS for each of these comparisons.
Risk factor score was 2.2  0.2 in African Americans and
2.8  0.2 in white subjects, p  0.07. Increase in CBF in
response to ACh alone was depressed (150% increase
above baseline) in 29 of 33 African Americans (88%) and in
29 of 33 white subjects. After ACh, constriction of the
epicardial coronary artery under study occurred in 13 of 33
African Americans (39%) and in 13 of 33 white subjects. Of
the three criteria defining endothelial dysfunction, 6 African
American and 4 Caucasian subjects had only one criteria; 14
and 17, respectively, had two criteria; and 13 and 12,
respectively, had all three criteria. The mean endothelial
dysfunction criteria score was identical (2.2  0.1) among
African American and Caucasian subjects. Left ventricle
mass indexed by height2.7, an allometric approach which
minimizes the contribution of obesity, was nearly identical
among African American and white subjects (53.5 
3 kg/m2.7 vs. 53.1  3 kg/m2.7). Left ventricular ejection
fraction was similar (66  2% vs. 68  2%) as was mean
arterial pressure (108  3 mm Hg vs. 102  2 mm Hg,
p  0.11). Serum creatinine (1.0  0.1 mg/dl vs. 0.9 
0.1 mg/dl), fasting glucose (125  13 mg/dl vs. 110 
9 mg/dl, p  0.24) and lipoprotein(a) (42  6 mg/dl vs.
27  6 mg/dl, p  0.14) were not significantly different.
The only value found to significantly differ between groups
was HDLC (51  3 mg/dl vs. 40  2 mg/dl, p  0.001).
Univariate linear regression analysis showed no significant
correlation between change in ACh stimulated CBF after
L-arginine and the following independent variables: base-
line peak ACh response before L-arginine, age, LVMI,
BMI, LDLC, HDLC, lipoprotein(a), adenosine response,
mean arterial pressure during testing, risk factor score and
endothelial dysfunction criteria score.
Of the 33 African American subjects, 19 (58%) were
being treated with potentially vasoactive medications. In six
cases (18%), vasoactive medications were taken within 12 h
of the procedure. This included two receiving coronary
vasodilator drugs and four receiving beta-antagonist drugs
in combination with coronary dilator and/or angiotensin-
Table 1. Individual Clinical Characteristics and Coronary Blood Flow Responses After L-Arginine in 33 African American Patients
Patient
Number
Age (yrs)
and Gender
BMI
(kg/m2)
LVMI
(g/m2)
LDLC
(mg/dl)
BP
(mm Hg) HTN DM Tob
Percentile Change
in AChP
After L-Arginine
1 20 M 27.2 97 82 100/74    27
2 25 M 26.2 120 168 120/80    47
3 28 M 37 128 132 125/98    25
4 31 M 25 119 105 112/85    278
5 34 M 27.8 148 179 160/122    62
6 35 M 27 113 125 130/84    110
7 36 M 27 156 194 110/85    114
8 37 M 34 113 194 158/95    9
9 43 M 25 104 82 120/80    13
10 43 F 36 130 86 115/90    32
11 44 M 18 81 103 140/85    5
12 44 M 23.3 98 119 110/75    0
13 44 M 34 114 46 140/78    36
14 45 M 24.9 142 116 170/108    65
15 46 F 35 121 98 216/120    16
16 47 M 26 100 122 146/100    195
17 47 F 42 154 158 158/96    56
18 48 M 35.6 115 120 120/85    26
19 49 M 24 109 154 122/85    22
20 50 F 29.2 102 96 134/76    19
21 50 F 33 67 78 150/92    34
22 50 F 47 88 65 200/102    27
23 51 F 40.2 118 165 200/120    9
24 53 F 35.7 142 201 185/95    29
25 54 M 26 104 120 138/96    6
26 56 F 27 103 81 150/88    104
27 60 F 25 90 143 140/75    2
28 61 M 27 191 143 145/85    14
29 63 M 26 108 121 148/82    63
30 64 F 29.9 103 97 148/72    15
31 66 M 24.4 120 122 130/82    21
32 68 F 28.7 113 90 160/80    7
33 72 F 29 105 111 175/90    10
AChP peak coronary blood flow response to intracoronary acetylcholine; BMI body mass index; BP blood pressure; LDLC low-density lipoprotein cholesterol; DM
history of diabetes mellitus; HTN  history of hypertension; LVMI  left ventricular mass indexed by body surface area; Tob  history of tobacco use.
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converting enzyme inhibitor drugs. Of the 33 white sub-
jects, 24 (73%) were being treated with potentially vasoac-
tive medications. In three cases (9%), vasoactive medications
were taken within 12 h of the procedure. This included one
receiving a coronary vasodilator drug and two receiving
beta-antagonist drugs in combination with an alpha-
adrenergic blocking drug or angiotensin-converting enzyme
inhibitor drug. Among the 26 female subjects, 11 of 13
African Americans were postmenopausal (three taking hor-
mone replacement therapy), one perimenopausal and one
premenopausal; 10 of 13 white subjects were postmeno-
pausal (four taking hormone replacement therapy), two
perimenopausal and one premenopausal.
Endothelium-dependent coronary vascular relaxation af-
ter L-arginine. Figure 1 shows the individual microvascu-
lar responses of the African American and white subjects.
The peak CBF response after ACh is shown at baseline and
then after intracoronary L-arginine for each subject. As a
group, African Americans showed significant enhancement
of ACh-mediated increase in CBF above baseline after
L-arginine when compared with before (120  12% vs.
76  9%, p  0.004). By contrast, the matched white
subjects as a group demonstrated no significant benefit after
L-arginine (90.2  11% vs. 86  10%). Figure 2 shows
absolute percentile improvement in peak ACh response
after intracoronary L-arginine in African Americans versus
white subjects, first partitioned by gender, then combined.
This figure demonstrates greater improvement among Af-
rican Americans as a group (44.5  10.3% vs. 4.2  6.4%,
p  0.0016), among African American men compared with
matched white men (55.6  16% vs. 8.1  9.8%, p 
0.016) and among African American women compared
Table 2. Individual Clinical Characteristics and Coronary Blood Flow Responses After L-Arginine in 33 White Patients Matched to
Those in Table 1
Patient
Number
Age (yrs)
and Gender
BMI
(kg/m2)
LVMI
(g/m2)
LDLC
(mg/dl)
BP
(mm Hg) HTN DM Tob
Percentile Change
in AChP
After L-Arginine
1 27 M 28.9 75 103 112/86    10
2 35 M 25.1 96 167 122/90    35
3 28 M 36 132 101 128/100    20
4 31 M 28 117 109 125/95    33
5 34 M 29 159 151 116/94    81
6 35 M 26.8 115 101 105/78    63
7 40 M 27 136 154 150/92    31
8 31 M 36 102 168 142/100    14
9 37 M 30 117 112 130/95    48
10 51 F 31.8 165 62 152/76    8
11 42 M 26.5 118 130 135/88    73
12 43 M 21 91 133 115/65    51
13 46 M 35.6 111 136 170/106    0
14 47 M 29 139 121 140/95    4
15 47 F 34.2 107 101 140/80    29
16 50 M 31 80 121 120/75    75
17 50 F 34 131 135 150/95    5
18 48 M 35.6 75 145 122/70    13
19 45 M 26 105 156 125/80    81
20 48 F 23.6 112 72 142/78    28
21 48 F 30.1 105 83 135/70    25
22 51 F 40 110 110 122/70    5
23 59 F 35.5 103 133 155/95    3
24 56 F 40 140 183 190/100    20
25 55 M 24.4 98 126 124/80    4
26 57 F 31 86 102 162/90    22
27 58 F 21 92 178 128/60    30
28 59 M 23 199 137 98/65    25
29 60 M 28.4 84 113 152/94    14
30 68 F 33 84 136 125/75    41
31 65 M 28.7 128 149 132/78    15
32 66 F 34 126 128 195/86    10
33 73 F 34.6 114 74 182/80    0
Abbreviations as in Table 1.
Table 3. Matching Clinical Characteristics in 33 Pairs of
African American and White Patients
African American
Subjects (n  33)
White Subjects
(n  33) p Value
Age (yrs) 47.4  2.2 48.2  2.1 0.8
BMI (kg/m2) 29.8  1.1 30.3  0.9 0.7
LVMI (g/m2) 115.6  4.2 113.7  4.7 0.8
LDLC (mg/dl) 121.7  6.7 125.2  5.2 0.7
Abbreviations as in Table 1.
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with matched white women (27.3 7.6% vs.1.7 6.2%,
p  0.007). Using Grubbs outlier analysis, the L-arginine
response of the subject with the largest improvement was
2 SD from the mean and was identified as a possible
outlier. The experimental procedure and study data were of
excellent quality, arguing against arbitrary removal. The
analysis was, however, repeated after removal of the single
largest responder after L-arginine (Table 1, Patient 4) and
the paired subject from Table 2. There were no changes in
the overall results. No other subject met criteria defining an
outlier. L-arginine infusion alone did not change baseline
CBF. Though not as dramatic an effect, L-arginine infusion
also resulted in a greater epicardial dilator response (as
measured by percent increase in coronary diameter) after
ACh in African Americans but not white subjects (0.33 
0.5% vs.2.2 0.7%, p 0.02). Finally, coronary vascular
resistance index (percentile change) was decreased after
L-arginine infusion followed by ACh provocation among
African Americans but not among matched white subjects
when compared with ACh provocation alone (10.7 
2.3% vs. 0.9  1.9%, p  0.0017).
Though our study lacks a control group of subjects with
none of the three criteria used to define endothelial dys-
function, four African American and four white subjects in
the matched study groups had normal vasodilator responses
to ACh, that is, CBF 150% above baseline and epicardial
dilation. Despite normal vasodilator function, the four
African Americans demonstrated further improvement in
ACh responses after L-arginine, yet the four white subjects
did not (24.8 13.5% vs.16.3 25.5% increase in CBF,
p  0.21), suggesting that L-arginine is efficacious even
among black, but not white, subjects with preserved endo-
thelial function. Furthermore, we studied an additional 15
Caucasian subjects (nine men, six women) with normal
coronary angiography who could not be matched to a
comparable African American subject and had normal
vasodilator responses to ACh but one or more risk factors
for CAD. These 15 had similar age, LVMI, LDLC and
BMI characteristics and demonstrated nearly identical mild
improvement in peak ACh responses after L-arginine when
compared with the larger matched Caucasian study group
(5.2  12% vs. 4.2  6%, p  NS).
DISCUSSION
Our study demonstrates that intracoronary L-arginine in-
fusion preferentially enhances microvascular relaxation after
ACh stimulation in African American subjects referred for
coronary angiography. This finding is independent of
gender. Both African American men and women demon-
strated greater augmentation of CBF after supplementary
L-arginine in comparison with Caucasian men and women
well matched for characteristics known to be associated with
endothelial dysfunction. The mechanism of improved re-
sponse was mediated through further reduction in coronary
microvascular resistance. Similarly, though to a lesser de-
gree, coronary epicardial dilation in response to ACh was
Figure 1. Individual peak percent increase in coronary blood flow above baseline in response to acetylcholine alone (AChHb) and then after repeated
administration of acetylcholine following infusion of L-arginine (AChH after L-Arg) is shown in 33 African Americans (left panel) and in 33 matched
white subjects (right panel). p  0.004.
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preferentially enhanced after L-arginine in African Ameri-
can subjects.
We studied patients with normal coronary arteries based
on angiographic assessment. Because angiographic assess-
ment of epicardial arteries is insensitive for detection of
atherosclerosis and endothelial dysfunction, we used other
criteria to define endothelial dysfunction: presence of coro-
nary risk factors, coronary artery constriction in response to
ACh infusion and CBF increase 150% above baseline in
response to ACh (1,4,9–12). Subjects with no angiographic
CAD and endothelial dysfunction are conjectured to repre-
sent an early stage in the natural history of CAD and
cardiomyopathy where reparative therapy of endothelial
dysfunction may serve to retard or prevent progressive
disease. This is a population of enormous importance in
preventive cardiology.
L-arginine-mediated augmentation of vascular relaxation.
For over 10 years now, supplementary L-arginine has been
reported to improve endothelium-dependent vasomotor
function in patients with endothelial dysfunction. Our study
is the first, to our knowledge, to investigate racial and
gender patterns in L-arginine responsiveness of the coro-
nary endothelium. Multiple candidate mechanisms for
efficacy of L-arginine have been proposed, including provi-
sion of substrate for endothelial cell NO synthase, indirect
antioxidant effects, competition with naturally occurring
NO synthase inhibitors such as asymmetric dimethyl-
arginine (ADMA), alteration of endothelial cell acid/base
microenvironments, attenuation of norepinephrine bioactiv-
ity, release of other vasoactive agents such as insulin and
histamine and provision of substrate for inducible NO
synthase (32–35).
Although the exact mechanism remains unknown in our
study, there are two that merit particular attention. First,
accumulation of ADMA preferentially among African
Americans would result in competitive inhibition of endo-
thelial NO synthase, which could be rapidly reversed by
supplemental L-arginine. Though there is no data about the
prevalence of increased plasma ADMA among African
Americans, it has been shown that ADMA levels are
increased in the presence of renal failure, hypercholesterol-
emia and peripheral vascular disease (33,34). More perti-
nent to our study, plasma ADMA concentration increased
and NO metabolites decreased after salt loading in salt-
Figure 2. Absolute percentile change in coronary blood flow in response to peak acetylcholine infusion after L-arginine infusion compared with peak
acetylcholine infusion alone. Data are shown for 13 African American and 13 matched white women; for 20 African American and 20 matched white men;
and for the total population of 33 African American and 33 matched white subjects.
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sensitive hypertensives (35). Although salt-sensitive hyper-
tension is present in both black and white subjects, it is
significantly more prevalent among African Americans,
providing a possible rationale for preferential L-arginine
benefit (36). Our study was not designed to measure
ADMA plasma levels or to test for salt sensitivity; therefore,
we can only speculate about this possible association. The
second mechanism of interest is attenuation of norepineph-
rine bioactivity, a non–NO-dependent mechanism. Argi-
nine has been shown to nonstereospecifically antagonize
responses to norepinephrine, a vascular smooth muscle
constrictor (37). This causes shifting of the norepinephrine
dose response curve to the right, thus lessening induced
arterial constriction during submaximal infusions. There is a
clinical basis for suspecting increased coronary contractile
sensitivity among African Americans. A consistent obser-
vation in previous studies is that black subjects exhibit
increased peripheral vasoconstriction in response to stimuli
that activate the sympathetic nervous system, such as exer-
cise, mental arithmetic, cold pressor stimuli and other forms
of behavioral coping challenge (38–40). Studies in the
brachial circulation have also found reduced vasodilation in
response to agonists in African Americans (41,42). Thus,
attenuation of norepinephrine bioactivity by L-arginine may
be a more important mechanism in African Americans
because of the propensity for increased contractile sensitiv-
ity.
Comparison with previous coronary artery studies. In
our study, there was only a modest average improvement in
ACh-mediated increase in CBF after L-arginine among the
Caucasian subjects (4.2  6.4%), though a broad range of
responses (81% to 81%). A total of 50% of Caucasian
subjects, but only 9% of African Americans, showed no
improvement after L-arginine (Tables 1 and 2). This is in
contrast to several previous studies that largely investigated
Caucasian patients with significant CAD (18,19). These,
together with another study that presented combined find-
ings of 24 patients with normal coronary angiography and
15 with CAD, reported significant improvement in CBF
responses to ACh after L-arginine (21). Our study group
differs importantly because it consists of subjects without
angiographic CAD. Another study that enrolled Japanese
subjects analyzed those with normal angiography and those
with mild disease separately, showing no improvement in
CBF responses after L-arginine in either group (17). In
addition to differing patient characteristics, previous studies
have used differing doses and/or modes of administration of
ACh and L-arginine, likely contributing to the divergent
findings.
Study limitations. Electronic digital calipers, as employed
in our study, are useful for performing serial angiographic
measurements because of simplicity and low cost of the
technology. Although this technique has been shown to
consistently overestimate the true diameter of phantoms,
when serial measurements are expressed as percent diameter
change from baseline (as done in our study), comparable
results were found using either digital calipers or automated
quantitative coronary angiography (43).
A placebo infusion for comparison with L-arginine infu-
sion during ACh testing was not performed because of the
additional time required during an already lengthy research
protocol. Consequently, reproducibility of ACh effect on
CBF response cannot be determined in our study. Other
studies, however, have reported excellent long-term stability
of ACh responses at baseline and after six months of
placebo (44–46).
Conclusions. We found that African American race pre-
dicts enhanced coronary vasodilator response to ACh after
L-arginine infusion in a referral cardiac population with
normal coronary arteriograms and endothelial dysfunction
after matching for age, gender, LVMI, LDLC and BMI.
This finding was independent of gender. Improvement
in microvascular function in African Americans after
L-arginine was mediated through further reduction in
coronary vascular resistance. If confirmed, our study sug-
gests that there are target populations in which L-arginine
supplementation may be particularly efficacious, especially
for amelioration of microvascular endothelial dysfunction.
Additional investigations studying enhancement of coro-
nary endothelium-dependent relaxation after L-arginine
in African American patients are needed to confirm our
findings and explore possible mechanisms.
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